Misplaced Pages

Dr Lal PathLabs

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Healthcare company
A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Misplaced Pages's content policies, particularly neutral point of view. Please discuss further on the talk page. (May 2022) (Learn how and when to remove this message)

Dr Lal PathLabs
Company typePublic
Traded asBSE: 539524
NSE: LALPATHLAB
IndustryHealthcare
Founded1949
FounderS. K. Lal
HeadquartersDelhi, India
Number of locations233
Key peopleArvind Lal (Chairman)
BrandsSwasthfit, Sugarnme, OncoPro, NephroPro
RevenueIncrease ₹2,987 crore (US$360 million) (FY22)
Net incomeIncrease ₹350 crore (US$42 million) (FY22)
Number of employees3941 (2019)
Websitewww.lalpathlabs.com

Dr Lal PathLabs Limited is an Indian service provider of diagnostic and related healthcare tests. Based in New Delhi, the company offers tests on blood, urine and other human body viscera.

History

Dr Lal PathLabs was started in 1949, by the late S. K. Lal. Lal was a Junior Doctor in the British Indian Army and studied pathology from the Armed Forces Medical College in Pune, with additional training in pathology at Cook County Hospital in Chicago. The main operation of Dr Lal PathLabs deals with the performing of diagnosis and testing, including routine tests (including blood tests), specialized tests (e.g., viral and bacterial infection tests) and preventive screenings.

In 2014, Dr Lal PathLabs acquired the APL Clinical Institute of Clinical Laboratory & Research Private Limited.

Dr Lal PathLabs launched its IPO in 2015. The company got listed on BSE and NSE on 23 December 2015.

In 2021, Dr Lal PathLabs acquired Suburban Diagnostics for an enterprise value of ₹925 crore in an all-cash deal.

Operations

Infrastructure

The company has 200 laboratories and diagnostic centres with approximately 5000+ collection centres across India. They have also worked with BD India to open a "Centre of Excellence in Phlebotomy", a centre for training healthcare in the process of safely collecting blood samples.

Laboratory Accreditations

Awards and recognition

Controversies

Zika outbreak

While Zika has not been reported in India (as of 6 February 2016), on 3 February 2016, Dr Lal PathLabs and other competing pathology labs announced they were preparing Zika test kits. Dr Lal PathLabs reported they plan to sell their kits for Rs 4500 (€60). However, several days later IndiaToday reported: "the Union Ministry of Health pulled up private players, saying they cannot cash in on a public health emergency" and also reported that Dr. Vandana Lal (executive director of Dr Lal PathLabs) stated: "We don't want to talk on this matter. We don't have any tests for Zika virus and we are also not importing any test kits for the same. If at all we plan to do something, we will take the government's prior permission."

Data breach

According to an October 2020 report, for months, the company stored hundreds of massive spreadsheets containing sensitive patient data in an Amazon Web Services storage bucket without a password. TechCrunch was the first news source to report the data breach.

References

  1. ^ "Dr Lal PathLabs – Our Labs".
  2. ^ "Dr Lal Pathlabs Q4 Results: Profit dips 27% to Rs 62 cr". The Economic Times. Retrieved 13 January 2023.
  3. "US PE firm in talks to buy 15% in Dr Lal PathLabs from Sequoia". The Economic Times. Retrieved 22 October 2021.
  4. "Dr Lal PathLabs". India Brand Equity Foundation. Retrieved 8 February 2016.
  5. Phadnis, Aneesh (1 December 2015). "Country's oldest path lab chain to go public with Rs 638-cr IPO". Business Standard India. Retrieved 22 October 2021.
  6. "Dr Lal Pathlabs Ltd". The Times of India. Retrieved 8 February 2016.
  7. "Dr Lal Pathlabs IPO To Open On Dec 8, Price Band Rs 540-550". Moneycontrol. Retrieved 22 October 2021.
  8. Mudgill, Amit (23 December 2015). "PathLabs, Alkem soar on stock market debut". The Economic Times. Archived from the original on 29 December 2015. Retrieved 2 February 2016.
  9. "Dr Lal Path Labs buys Suburban Diagnostics in all-cash deal". The Economic Times. Retrieved 13 January 2023.
  10. "BD India and Dr Lal PathLabs launch COE in phlebotomy". The Financial Express. 8 July 2015. Retrieved 10 February 2016.
  11. "Organisers & Partners". eletsonline.com. Retrieved 14 February 2016.
  12. "DIRECTORY of ACCREDITED MEDICAL TESTING LABORATORIES". nabl-india.org. Retrieved 14 February 2016.
  13. "Cnbc Tv18 Emerging India Award". moneycontrol.com. Retrieved 14 February 2016.
  14. "Take a look at winners of VCCircle Healthcare Awards 2013". VCCircle. Retrieved 14 February 2016.
  15. "FROST & SULLIVAN 4th ANNUAL INDIA HEALTHCARE EXCELLENCE AWARDS 2012". frost.com. Retrieved 14 February 2016.
  16. "FICCI Healthawards 2018". www.ficcihealthawards.com. Retrieved 31 January 2019.
  17. "In India, Zika detection test to hit market by March, cost pegged at Rs 5,000". Hindustan Times. 3 February 2016. Retrieved 10 February 2016.
  18. "Health Ministry pulls up laboratories for trying to cash in on Zika scare". India Today. Retrieved 10 February 2016.
  19. "Dr Lal PathLabs leaks millions of patients data in public domain: Report". The Indian Express. 10 October 2020. Retrieved 19 May 2022.
  20. Ahaskar, Leroy Leo, Abhijit (8 October 2020). "Dr Lal PathLabs left critical patient data exposed on public server". mint. Retrieved 19 May 2022.{{cite web}}: CS1 maint: multiple names: authors list (link)

External links

India NIFTY 200 companies
NIFTY
200
NIFTY
100
NIFTY
50
NIFTY
Next 50
Categories: